Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can tiny electric acupuncture needles help women with low egg reserve conceive?

NCT ID NCT07769684

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial tests whether electro-thumbtack needle (ETN) therapy, a form of acupuncture with mild electrical stimulation, can improve the live birth rate in women with diminished ovarian reserve (DOR) undergoing in vitro fertilization (IVF). About 406 women with DOR will be randomly assigned to receive either real ETN or a placebo version, starting 1-3 menstrual cycles before IVF and continuing until the trigger shot. Researchers will compare pregnancy outcomes, egg quality, and emotional well-being between the two groups to see if ETN makes a meaningful difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
electro-thumbtack needle (ETN) therapy, a form of acupuncture with electrical stimulation
What this could lead to
If effective, this could offer a drug-free way to improve IVF success in women with diminished ovarian reserve, potentially increasing their chances of having a baby.
What could go wrong
This is an early-stage trial, and results may not confirm benefit. The therapy is generally safe, but individual responses can vary, and it may not improve outcomes for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 406 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 42 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Age between 20-42 years old; * 2\. Meet the DOR diagnostic criteria: Diagnosis of diminished ovarian reserve (DOR) can be made if any two of the following three criteria are met: ①Serum AMH level ≤ 1.1 ng/mL; ②On days 2-4 of the menstrual cycle, transvaginal ultrasound demonstrates a total number of basal antral follicles (diameter 2-10 mm) in both ovaries \<7 (antral follicle counting, AFC); ③For two consecutive menstrual cycles, on days 2-4, serum FSH levels range from 10 U/L to \<25 U/L. * 3\. Semen routine examination of the participant's spouse is normal: sperm concentration ≥15×10⁶/mL, proportion of forward-moving sperm ≥32%, proportion of normally shaped sperm ≥4%; * 4\. Intend to undergo In Vitro Fertilization - Embryo Transfer (IVF-ET); * 5\. Voluntarily participate in this study, sign the informed consent form, and be able to cooperate to complete the treatment and follow-up. Exclusion Criteria: * 1\. Chromosomal or genetic abnormalities in the female or male partner; * 2\. History of ovarian surgery, such as surgery for ovarian teratomas or ovarian chocolate cysts; * 3\. Uterine abnormalities that may affect embryo implantation (including uterine malformations, uterine tuberculosis, adenomyosis, and submucosal myomas \>4 cm); * 4\. Unresolved intrauterine adhesions, endometritis, or endometrial polyps; * 5\. The female partner has uncorrected endocrine disorders such as uncomplicated hyperthyroidism or hypothyroidism, hyperprolactinemia, insulin resistance, diabetes, adrenal diseases, or has taken antipsychotic medications in the past 3 months; * 6\. The female partner has a confirmed diagnosis of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, Sjögren's syndrome, or Hashimoto's thyroiditis; * 7\. Three or more failed embryo transfers; * 8\. History of malignant tumors in the female or male partner with prior radiotherapy or chemotherapy; * 9\. The female partner has received acupuncture or press needle therapy in the past 3 months; * 10\. Use of Chinese herbal decoctions or granules during treatment; * 11\. Abnormal semen analysis in the male partner; * 12\. Refusal to undergo in vitro fertilization - embryo transfer (IVF-ET); * 13\. Refusal to sign the informed consent form for this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diminished ovarian reserve (DOR) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shiyan People's Hospital

    Shiyan, Hubei, 442000, China

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

  • Wuhan Jinxin Gynecology and Obstetrics Hospital of Integrative Medicine

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.